In the last trading session, 1.39 million shares of the G1 Therapeutics Inc (NASDAQ:GTHX) were traded, and its beta was 1.80. Most recently the company’s share price was $4.77, and it changed around -$0.21 or -4.22% from the last close, which brings the market valuation of the company to $249.38M. GTHX currently trades at a discount to its 52-week high of $6.14, offering almost -28.72% off that amount. The share price’s 52-week low was $1.08, which indicates that the current value has risen by an impressive 77.36% since then. We note from G1 Therapeutics Inc’s average daily trading volume that its 3-month average coming to 1.67 million.
G1 Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.83. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended GTHX as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. G1 Therapeutics Inc is expected to report earnings per share of -$0.17 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
G1 Therapeutics Inc (NASDAQ:GTHX) trade information
Instantly GTHX has showed a red trend with a performance of -4.22% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently up 56.39% year-to-date, but still up 6.24% over the last five days. On the other hand, G1 Therapeutics Inc (NASDAQ:GTHX) is 1.92% up in the 30-day period.
G1 Therapeutics Inc (GTHX) estimates and forecasts
G1 Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 226.71 percent over the past six months and at a 40.86% annual growth rate that is well above the industry average of 12.90%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -221.40% in revenue this quarter, and will report an increase of 62.90% in the next quarter. The year-over-year growth rate is expected to be -12.40%, down from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of $16.45 million in revenue for the current quarter. 6 analysts expect G1 Therapeutics Inc to make $18.17 million in revenue for the quarter ending Sep 2024. The company’s sales for the same quarters a year ago were $42.39 million and $12.3 million respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -61.20%. Forecasts for the next quarter put sales growth at 47.70%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 18.38%.
